SL Science Holding Ltd (SLBT) AI Stock Analysis

11 Followers

SL Science Holding Ltd

(NASDAQ:SLBT)

Select Model

Rating:42Neutral

Price Target:$1.00▼(-18.03% Downside)

Action:initiatedcoverage

Date:10/27/26

The score is driven primarily by weak financial performance (deepening losses, margin compression, and renewed cash burn that raises financing risk). Technicals add further pressure, with the stock trading below key moving averages and negative momentum indicators alongside very high volatility. Valuation offers limited support because the provided P/E and dividend yield are not usable for assessment.

Positive Factors

Interim Revenue GrowthYear-on-year revenue growth in the latest interim period indicates that the company is expanding its commercial activity and may be building a larger operating base. If sustained, this growth could provide greater capacity to absorb fixed costs and support investment in future products or market development.

Negative Factors

Deepening Operating LossesThe company is not currently converting revenue into sustainable earnings, with losses deepening and expenses rising faster than sales. Persistent operating underperformance can consume the benefit of revenue growth, require additional funding, and make future profitability dependent on significant cost discipline or improved scale.

SL Science Holding Ltd (SLBT) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $684.13M
Dividend Yield: ―
Average Volume (3M): 64.35K
Price to Earnings (P/E): 0.0
Beta (1Y): 5.42
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 15
Sector: General
Sector Strength: 55
Industry: Biotechnology

SL Science Holding Ltd Business Overview & Revenue Model

Company Description

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research...

SL Science Holding Ltd Financial Statement Overview

Summary

Financial performance is weak: profitability deteriorated from a profitable 2023 to sizable losses in 2024 and deeper losses in 2025, with material margin compression (gross margin down to ~35% in 2025). Cash flow also worsened sharply, with operating cash flow turning to a large outflow in 2025 and free cash flow materially negative, increasing near-term financing risk. A positive offset is low leverage (debt-to-equity ~0.09 in 2025), but the equity base has fallen significantly, reflecting the strain from losses.

Income Statement

24Negative

Balance Sheet

58Neutral

Cash Flow

27Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023
Income Statement
Total Revenue	―	2.20M	3.36M	878.97K
Gross Profit	―	775.06K	1.93M	738.01K
EBITDA	-1,602	-3.74M	-1.15M	134.02K
Net Income	-1,602	-3.82M	-1.19M	399.04K
Balance Sheet
Total Assets	5.79M	2.82M	5.93M	4.24M
Cash, Cash Equivalents and Short-Term Investments	3.37M	1.26M	3.68M	276.85K
Total Debt	305.67K	213.41K	0	550.06K
Total Liabilities	1.06M	533.28K	204.90K	668.07K
Stockholders Equity	4.73M	2.28M	5.73M	3.57M
Cash Flow
Free Cash Flow	-450	-2.23M	272.19K	-2.64M
Operating Cash Flow	-134	-1.91M	280.16K	-2.45M
Investing Cash Flow	-316	-319.69K	123.28K	-182.98K
Financing Cash Flow	-614	-879.14K	3.07M	2.86M

SL Science Holding Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SLBT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
RNXT	54Neutral	$56.86M	-4.08	-145.63%	―	198.49%	16.29%
TVGN	48Neutral	$36.40M	-1.01	248.50%	―	―	36.06%
INMB	45Neutral	$38.30M	-1.91	-82.87%	―	-100.00%	72.25%
SLBT	42Neutral	$684.13M	0.00	-95.36%	―	―	―
ABVC	41Neutral	$26.16M	-3.34	-71.47%	―	-100.00%	-55.90%

* General Sector Average

Performance Comparison

SLBT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SLBT	SL Science Holding Ltd	1.22	-2.11	-63.36%
INMB	Inmune Bio	1.32	-0.45	-25.42%
ABVC	ABVC BioPharma, Inc.	0.98	-1.91	-65.92%
RNXT	Renovorx, Inc.	1.29	0.26	25.24%
TVGN	Tevogen Bio Holdings Inc.	5.92	-20.33	-77.45%

SL Science Holding Ltd Corporate Events

SL Science Holding Files Form 6-K Detailing First-Half 2026 Results

Oct 26, 2026

On October 26, 2026, SL Science Holding Limited filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing unaudited interim consolidated financial statements and management’s discussion and analysis for the six months ended...

SL Science Holding Adopts Cayman Islands Governance Exemptions on Nasdaq

Sep 24, 2026

On September 24, 2026, SL Science Holding Limited filed a Form 6-K announcing that, as a Cayman Islands-incorporated foreign private issuer on Nasdaq, it has elected to follow certain home country corporate governance practices. The company confirmed...

SL Science Holding Discloses Resignation of Vice President of Finance

Sep 1, 2026

On August 24, 2026, SL Science Holding Limited’s vice president of finance, Johnson Lau, tendered his resignation to the board of directors, with the board accepting his departure effective August 31, 2026. The company stated that Lau’s r...

SL Science Holding Ltd Switches Audit Firm to TAAD LLP in Late August 2026

Aug 27, 2026

On August 21, 2026, SL Science Holding Ltd appointed TAAD LLP as its new independent registered public accounting firm, following the dismissal of ARK Pro CPA & Co on August 20, 2026 after an evaluation process approved by the audit committee. Th...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026

SL Science Holding Ltd AI Stock Analysis